Hologic, Inc. (NASDAQ:HOLX) Stock Position Trimmed by Anchor Investment Management LLC

Anchor Investment Management LLC decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 5.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,530 shares of the medical equipment provider’s stock after selling 400 shares during the period. Anchor Investment Management LLC’s holdings in Hologic were worth $543,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HOLX. Brooklyn Investment Group grew its holdings in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 145 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC increased its holdings in shares of Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares during the period. UMB Bank n.a. raised its stake in shares of Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after purchasing an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc lifted its holdings in Hologic by 3.6% in the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 1.7 %

Shares of NASDAQ HOLX opened at $57.86 on Wednesday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $56.27 and a twelve month high of $84.67. The company’s fifty day moving average is $62.04 and its 200-day moving average is $71.25. The stock has a market cap of $12.98 billion, a price-to-earnings ratio of 18.25, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Stephens reiterated an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Hologic has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.